Agilent Launches BioTek Cytation 9 to Accelerate Cell Biology Research
Event summary
- Agilent Technologies Inc. launched the BioTek Cytation 9 cell imaging multimode reader on April 1, 2026.
- The new device combines multimode microplate reading and high-content cell imaging in a single platform.
- Cytation 9 offers twice the imaging speed and expanded capabilities, including inverted fluorescence microscopy and upright imaging.
- The product is designed to support pharmaceutical and biotechnology laboratories in drug discovery and disease research.
The big picture
Agilent's launch of the BioTek Cytation 9 underscores the growing demand for integrated, high-throughput solutions in cell biology research. The product's enhanced capabilities align with industry trends toward automation and faster data analysis in drug discovery. With a decade of Cytation innovation, Agilent aims to solidify its position in the competitive biotechnology instrumentation market.
What we're watching
- Market Adoption
- How quickly pharmaceutical and biotechnology labs will integrate Cytation 9 into their workflows.
- Competitive Positioning
- Whether Agilent can maintain its leadership in cell imaging technology against competitors.
- Revenue Impact
- The pace at which Cytation 9 sales will contribute to Agilent's overall revenue growth.
Related topics